• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Beyond High-Risk Lesions: HPV Vaccination and Impact on Invasive Cervical Cancer Risk

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • HPV vaccine has been shown to be effective at preventing high-grade cervical lesions
    • However, direct effect of quadrivalent HPV vaccine on the risk of invasive cervical cancer remains limited
  • Lei et al. (NEJM, 2020) used a large cohort to examine the association between HPV vaccination and the risk of invasive cervical cancer

METHODS:

  • Cohort study
  • Participants
    • Girls and women
    • 10 to 30 years
    • Living in Sweden (from 2006 to 2017)
  • Study design
    • Received at least one dose of vaccine
    • Analysis controlled for
      • Age at follow-up | Calendar year | County of residence | Parental characteristics (education, household income, mother’s country of birth, and maternal disease history)
  • Primary outcome
    • Invasive cervical cancer

RESULTS:

  • 1,672,983 girls and women included
  • Cervical cancer diagnoses
    • Women who received the HPV vaccine: 19 diagnoses
    • Women who had not received the HPV vaccine: 538 diagnoses
  • Cumulative incidence of cervical cancer
    • Received vaccination: 47 cases per 100,000 persons
    • Did not receive vaccination: 94 cases per 100,000 persons
  • Women who were vaccinated were 0.51 times less likely to experience cervical cancer compared to controls (adjusted for age at follow-up)
    • Incidence rate ratio (IRR) 0.51 (95% CI, 0.32 to 0.82)
    • After additional adjustment for other covariates, IRR was 0.37 (95% CI, 0.21 to 0.57)
  • IRR following adjustment for all covariates
    • Vaccinated <17 years
      • IRR 0.12 (95% CI, 0.00 to 0.34)
    • Vaccinated at 17 to 30 years
      • IRR 0.47 (95% CI, 0.27 to 0.75)

CONCLUSION:

  • In Sweden, quadrivalent HPV vaccination among women ages 10 to 30 was associated with reduced risk of invasive cervical cancer
  • If vaccination initiated <17 years of age, the risk for cervical cancer was 88% lower vs the cohort that had never been vaccinated | Based on the confidence interval, the plausible risk was 66 to 100% lower with vaccination
  • The authors conclude

HPV vaccination was associated with a substantially reduced risk of invasive cervical cancer

Learn More – Primary Sources:

HPV Vaccination and the Risk of Invasive Cervical Cancer

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

HPV Vaccines: Cochrane Reviews Looks at the Evidence with Multi-Year Follow-Up
The HPV Vaccine Leads to a Reduction in Cervical Precancers in Young Women in the U.S.
How has HPV Prevalence Changed Since Introduction of Vaccine?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site